Evidence map›Paper›PMID 33232375›Full record

ArticlePloS one2020

Acacetin suppresses the electrocardiographic and arrhythmic manifestations of the J wave syndromes.

José M Di Diego, Bence Patocskai, Hector Barajas-Martinez, Virág Borbáth, Michael J Ackerman, Alexander Burashnikov, Jérôme Clatot, Gui-Rong Li, Victoria M Robinson, Dan Hu and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Primary Electrical Heart Disease-Principles of Pathophysiology and Genetics.International journal of molecular sciences · 2024
    Review
  3. Functional identification of hot-spot mutations in cardiac calcium channel genes associated with the J wave syndromes.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. J wave syndromes: What's new?Trends in cardiovascular medicine · 2022
    Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Acacetin as a Potential Protective Compound against Cardiovascular Diseases.Evidence-based complementary and alternative medicine : eCAM · 2022
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 4 countries.

José M Di DiegoLankenau Institute for Medical Research, Wynnewood, PA, United States of America.ORCID 0000-0003-4570-6659
Bence PatocskaiDepartment of Cardiology, Angiology and Pulmonology, University Hospital, Heidelberg University, Heidelberg, Germany.
Hector Barajas-MartinezLankenau Institute for Medical Research, Wynnewood, PA, United States of America.
Virág BorbáthFirst Department of Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Michael J AckermanDivisions of Heart Rhythm Services and Pediatric Cardiology, Departments of Cardiovascular Medicine, Pediatric and Adolescent Medicine, and Molecular Pharmacology & Experimental Therapeutics, Windland Smith Rice Genetic Heart Rhythm Clinic and Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, MN, United States of America.
Alexander BurashnikovLankenau Institute for Medical Research, Wynnewood, PA, United States of America.
Jérôme ClatotLankenau Institute for Medical Research, Wynnewood, PA, United States of America.
Gui-Rong LiXiamen Cardiovascular Hospital, Medical School of Xiamen University, Xiamen, China.
Victoria M RobinsonLankenau Institute for Medical Research, Wynnewood, PA, United States of America.
Dan HuDepartment of Cardiology and Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Wuhan, China.
Charles AntzelevitchLankenau Institute for Medical Research, Wynnewood, PA, United States of America.
Lankenau Institute for Medical Research · USHeidelberg University · DEThomas Jefferson University · USMayo Clinic · USWuhan University · CNXiamen University · CN

Funding

ELECTRICAL HETEROGENEITY AND CARDIAC ARRHYTHMIASR01HL047678 · NHLBI · MASONIC MEDICAL RESEARCH LABORATORY, INC · PI ANTZELEVITCH, CHARLES · 1993 to 2014
$5.7M
Development of a whole heart model of the J wave syndromes and novel approaches to pharmacologic management of associated life-threatening arrhythmiasR01HL152201 · NHLBI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI ANTZELEVITCH, CHARLES, DI DIEGO, JOSE M. · 2020 to 2023
$2.5M
Novel Approaches to Pharmacologic Management of Life-Threatening Arrhythmias Associated with the J Wave SyndromesR56HL138103 · NHLBI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI ANTZELEVITCH, CHARLES · 2018 to 2018
$413k
NHLBI NIH HHS R01 HL047678NHLBI NIH HHS R01 HL152201NHLBI NIH HHS R56 HL138103
6 · The paper itself

Abstract

backgroundJ wave syndromes (JWS), including Brugada (BrS) and early repolarization syndromes (ERS), are associated with increased risk for life-threatening ventricular arrhythmias. Pharmacologic approaches to therapy are currently very limited. Here, we evaluate the effects of the natural flavone acacetin.

methodsThe effects of acacetin on action potential (AP) morphology and transient outward current (Ito) were first studied in isolated canine RV epicardial myocytes using whole-cell patch clamp techniques. Acacetin's effects on transmembrane APs, unipolar electrograms and transmural ECGs were then studied in isolated coronary-perfused canine RV and LV wedge preparations as well as in whole-heart, Langendorff-perfused preparations from which we recorded a 12 lead ECG and unipolar electrograms. Using floating glass microelectrodes we also recorded transmembrane APs from the RVOT of the whole-heart model. The Ito agonist NS5806, sodium channel blocker ajmaline, calcium channel blocker verapamil or hypothermia (32°C) were used to pharmacologically mimic the genetic defects and conditions associated with JWS, thus eliciting prominent J waves and provoking VT/VF.

resultsAcacetin (5-10 μM) reduced Ito density, AP notch and J wave area and totally suppressed the electrocardiographic and arrhythmic manifestation of both BrS and ERS, regardless of the experimental model used. In wedge and whole-heart models of JWS, increasing Ito with NS5806, decreasing INa or ICa (with ajmaline or verapamil) or hypothermia all resulted in accentuation of epicardial AP notch and ECG J waves, resulting in characteristic BrS and ERS phenotypes. Phase 2-reentrant extrasystoles originating from the RVOT triggered VT/VF. The J waves in leads V1 and V2 were never associated with a delay of RVOT activation and always coincided with the appearance of the AP notch recorded from RVOT epicardium. All repolarization defects giving rise to VT/VF in the BrS and ERS models were reversed by acacetin, resulting in total suppression of VT/VF.

conclusionsWe present experimental models of BrS and ERS capable of recapitulating all of the ECG and arrhythmic manifestations of the JWS. Our findings provide definitive support for the repolarization but not the depolarization hypothesis proposed to underlie BrS and point to acacetin as a promising new pharmacologic treatment for JWS.

Indexed as

Brugada SyndromeElectrocardiographyAjmalineAnimalsDisease Models, AnimalDogsDrug Evaluation, PreclinicalFlavonesHEK293 CellsHumansHypothermiaMyocytes, CardiacPericardiumPhenylurea CompoundsTetrazolesVerapamil1-(3,5-bis-trifluoromethylphenyl)-3-(2,4-dibromo-6-(1H-tetrazol-5-yl)phenyl)ureaacacetinAjmalineFlavonesPhenylurea CompoundsTetrazolesVerapamil

Identifiers

PMID33232375
PMCPMC7685455
OpenAlexW3108907509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.